Goldman Sachs Maintains Sell on Ionis Pharmaceuticals, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a 'Sell' rating on Ionis Pharmaceuticals (NASDAQ:IONS) but raises the price target from $25 to $28.
November 03, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite the raised price target from $25 to $28, Goldman Sachs maintains a 'Sell' rating on Ionis Pharmaceuticals.
The 'Sell' rating maintained by Goldman Sachs indicates a negative outlook for Ionis Pharmaceuticals. However, the raised price target suggests a slightly less bearish view than before. This could lead to short-term downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100